Good point! To add to this I just read a paper that showed near complete loss of OHC and 2/3 loss of IHC in a cat following extreme noise induced cochlear damage, and after they ran the histology reports a year later they found that the majority of support cells still remained intact.
There is a thing that tends to have good outcomes called cochlear pumping and recent research suggests that the technique can get medicine deep into the cochlear.
If that's the case that FX-322 will most likely be cheaper than hearing aids then I reckon the NHS will fully cover it just like they cover hearing aids.
There's probably a lot more to these calculations and costs than my naive assumption, but that is an estimate of £1267.61 per person.
Governments anywhere don't always act the smartest.
Governments negotiating for pharmaceutical pricing deals is not new and has been going on for sometime. Stuff like this has happened with the SARS-CoV-2 vaccines and deals being struck to obtain these both from a price and supply perspective. The same has happened in Australia over many years with more mainstream medicine like heart medicine but also with more specialist medicine like treatment for Cystic Fibrosis that would have cost the takers $1000s if this was needing to be sourced on their own. Obviously the benefit is also there for the pharmaceutical company due to their ability to mass produce and also gain more sales than they would have otherwise if the deal hadn't been reached.
This news might probably have given Frequency Therapeutics' stocks a boost. It just went from 33 dollars to 39 dollars. Some peeps probably think that the company will prop up some good news on this conference.
A clever manipulative move from insiders, seems like they sell every week to entice speculative buyers leading up to the 90-day. Great for swing traders and those with sensorineural hearing loss - no need to FREQ out, it's good news!
It is irritating, however the FDA process is necessary and also a good system to ensure what comes out is beneficial and safe. I don't like possibly having to wait, however it is necessary.
Probably depends on what's causing the additional hearing loss. If it's standard hair cell loss and there aren't confounding genetic issues (e.g., Otoferlin abnormalities), I think so.
I'm not sure how much of this is just positive corporate speak, but it was pleasant to read all the same.
Take care of your ears as best as possible before it comes out (and even after).
It's likely that an end to the pandemic would mean:
I don't think that this can easily be answered. At this stage I don't know whether even Frequency Therapeutics knows how to give candidates the best outcomes from FX-322. Hence how they have said that they might look at things like reformulation and redosing after the completion of the clinical trials.
It probably would lead to faster distribution in countries which require their own regulator to approve medicine. Therefore eliminating the need to potentially travel for some people.
That's a good question. If there is a Phase 3, it won't take as long because there really isn't a question anymore of "if it works".
There will be if they can show positive results in their current Phase 2a clinical trial. It will be easier to prove that FX-322 works as improved hearing is not a placebo.
Member
